Generic Medicine Info
Indications and Dosage
Ventricular tachycardia
Adult: Given as internittent IV bolus inj, 40 mg every 5 minutes. Max total dose: 5 mg/kg.
Phaeochromocytoma, heart failure not caused by hypertension.
Special Precautions
Renal impairment, cerebrovascular disorders, ischaemic heart disease, history of peptic ulceration or asthma. Hypotensive effect may be increased by exercise and heat. Increased risk of CV collapse or cardiac arrest in patients undergoing surgery.
Adverse Reactions
Severe postural and exertional hypotension, diarrhoea, dizziness, syncope, muscle weakness, lassitude, angina, renal insufficiency, transient cerebral ischaemia, bradycardia, failure of ejaculation, fatigue, headache, salt and water retention, oedema, breathlessness, overt heart failure, nausea, vomiting, dry mouth, nasal congestion, parotid tenderness, blurring of vision, depression, myalgia, muscle tremor, paraesthesias, hair loss, dermatitis, disturbed micturition, priapism, aggravation or precipitation of asthma, exacerbation of peptic ulcer, haematological effects.
Drug Interactions
Adrenaline, amfetamine, other sympathomimetics, TCAs, MAOIs, phenothiazine derivatives and related antipsychotics, oral contraceptives, digoxin or other digitalis derivatives, thiazide diuretics, other antihypertensives, levodopa, alcohol.
Mechanism of Action: Betanidine acts by selectively inhibiting transmission in postganglionic adrenergic nerves. It acts mainly by preventing the release of noradrenaline at nerve endings; it causes depletion of noradrenaline stores in the peripheral sympathetic nerve terminals. It does not prevent the release of catecholamines by the adrenal medulla.
MIMS Class
Other Antihypertensives
Disclaimer: This information is independently developed by MIMS based on Betanidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in